How India Exports Instrument to the World

The U.S. Food and Drug Administration (FDA) maintains the Orange Book, which lists approved drug products and their therapeutic equivalence evaluations. The Orange Book is updated daily to reflect new generic drug approvals, providing current information on approved generic products.

The regulatory pathway for instruments under HS Code 30061010 involves submitting an Abbreviated New Drug Application (ANDA) to the FDA. This process requires demonstrating bioequivalence to a reference listed drug (RLD) and compliance with current Good Manufacturing Practices (cGMP). Given that 77 Indian exporters are actively involved in exporting these instruments to the U.S., it is imperative for each to ensure adherence to FDA regulations to maintain market access.

In the European Union, the European Medicines Agency (EMA) oversees the marketing authorization of medicinal products. Manufacturers must obtain a Marketing Authorization (MA) before products can be marketed. This process involves a rigorous evaluation of quality, safety, and efficacy. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for granting MAs. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory, ensuring that products are consistently produced and controlled to quality standards.

The World Health Organization (WHO) maintains the Model List of Essential Medicines, which serves as a guide for countries to develop their own national lists. Inclusion in this list indicates a medicine's importance in a basic health system. Additionally, WHO's Prequalification Programme assesses the quality, safety, and efficacy of medicinal products, facilitating their procurement by UN agencies and member states. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is crucial for global market acceptance.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies drugs into various schedules under the Drugs and Cosmetics Act. The classification determines the level of control over the sale and distribution of the drug. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of scheduled drugs under the Drug Price Control Order (DPCO). Manufacturers of non-scheduled drugs are not required to take price approvals from NPPA. For exports, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) may be required, depending on the product and destination country regulations.

The FDA's Orange Book lists patents covering brand-name drugs, including those related to active ingredients, formulations, and methods of use. This information allows generic manufacturers to identify patents that may affect their ability to market generic versions. Understanding the patent landscape is essential for assessing the potential for generic competition and market entry strategies.

In May 2025, the FDA released draft guidance for industry on replacing color additives in approved or marketed drug products, providing recommendations for manufacturers considering such changes.

In January 2026, the Congressional Research Service published a report on patent listing in the FDA's Orange Book, offering insights into the regulatory framework and its implications for generic drug competition.

These developments underscore the dynamic nature of the regulatory environment and the importance of staying informed to ensure compliance and strategic market positioning.

India's pharmaceutical industry, including the production of medical instruments, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of KSMs used in Indian API manufacturing are sourced from China, making the supply chain vulnerable to disruptions.

Recent geopolitical tensions have exacerbated these vulnerabilities. In March 2026, the Strait of Hormuz was effectively blockaded by Iran, halting maritime traffic and severely disrupting global trade routes. This blockade has led to significant delays and increased costs in the transportation of raw materials essential for API production. (lemonde.fr)

The export market for medical instruments from India is notably concentrated. The top five exporters account for 55.1% of total exports, with MERIL ENDO SURGERY PRIVATE LIMITED leading at 16.0%. Such concentration poses a risk, as disruptions affecting these key suppliers could significantly impact the overall supply chain.

To mitigate this risk, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing and reduce dependency on imports. In November 2024, two greenfield plants were inaugurated under this scheme to produce critical pharmaceutical ingredients, marking a significant step toward self-reliance.

The closure of the Strait of Hormuz in March 2026 has had profound implications for global shipping, particularly affecting the transportation of medical instruments. The blockade has led to increased shipping costs and delays, as vessels are forced to reroute or halt operations. (lemonde.fr)

Additionally, heightened tensions in the Red Sea and the Strait of Hormuz have raised concerns about the safety of commercial shipping. Incidents of attacks on vessels have been reported, further complicating logistics and increasing insurance premiums for shipments.

• Diversify Supplier Base: Expand the network of suppliers beyond the current top exporters to reduce dependency on a limited number of sources.

• Enhance Domestic Production: Accelerate initiatives under the PLI scheme to bolster domestic manufacturing capabilities for both finished instruments and critical components.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics pathways to circumvent geopolitical hotspots, ensuring more reliable delivery schedules.

• Strengthen Inventory Management: Increase buffer stocks of essential raw materials and finished products to cushion against supply chain disruptions.

• Monitor Geopolitical Developments: Implement a robust system for tracking geopolitical events that could impact supply chains, enabling proactive risk management.

RISK_LEVEL: HIGH